A round up of all the latest news on www.globaluniversityventuring.com for our subscribers.
Manus Bio makes series A breakthrough
The MIT spinout has raised $19.4m from unnamed backers, and the plant-based ingredient developer will use the cash to expand its production capacity.
Tsinghua to host corporate-backed blockchain hub
Oben has co-founded a $5m blockchain research project based at Tsinghua University’s PBC School of Finance, while Tencent is also a backer.
Xcelerator embraces first cohort
The Tel Aviv University-backed accelerator, formed in partnership with the Israel Security Agency, has welcomed its first seven participants.
Liquidia looks to fill up with IPO funding
Liquidia Technologies, a spinout from UNC Chapel Hill, has filed to raise up to $57.5m in its initial public offering.
Facebook processes Bloomsbury AI addition
Natural language processing technology developer Bloomsbury AI has joined Facebook for up to $30m, enabling UCL Technology Fund to exit.
Université PSL assembles deep tech fund
PSL Innovation Fund will be managed by Elaia Partners and has targeted an $87.5m close having secured several corporates as backers.
VarmX firms up $8.7m series A
Leiden thrombosis therapy spinout VarmX had raised an undisclosed seed sum in June 2017 and converted debt to equity in its latest round.
Walshe finds his place with Map
Campbell Walshe has returned to Melbourne Accelerator Program as director, having co-founded a participant and been an entrepreneur-in-residence.
Cerebri celebrates $5m series A
Customer engagement platform Cerebri AI has received funding from University of Texas’s Horizon Fund having been co-founded by an ex-student.
Clearbridge crosses over to $4.8m round
Precision oncological diagnostics developer Clearbridge BioMedics is planning to float, almost a decade after it was spun out from National University of Singapore and Smart Centre.
Neurable interfaces with Michigan in series A round
Michigan student-run Zell Lurie Commercialization Fund has returned to back Neurable’s neurological activity-based VR and AR technology.
Forty Seven fetches $112m in IPO
The cancer drug developer and Stanford spinout floated at the top of its range in an offering that could reach $129m.


